{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:56:07Z","timestamp":1790276167712,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1995,2,1]],"date-time":"1995-02-01T00:00:00Z","timestamp":791596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":9095,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1995,2]]},"DOI":"10.1093\/oxfordjournals.annonc.a059108","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T17:06:20Z","timestamp":1486141580000},"page":"133-140","source":"Crossref","is-referenced-by-count":77,"title":["Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors"],"prefix":"10.1016","volume":"6","author":[{"given":"G.","family":"Catimel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.G.","family":"Chabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Guastalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dumortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gouyette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mathieu-Bou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mahjoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0005","first-page":"3888","article-title":"Plant antitumor agents I","volume":"88","author":"Wall","year":"1966","journal-title":"The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0010","first-page":"747","article-title":"Lethal activity of camptothecin sodium on human lymphoma cells","volume":"34","author":"Drewinko","year":"1974","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0015","first-page":"789","article-title":"Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin","volume":"46","author":"Gallo","year":"1971","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0020","first-page":"25","article-title":"Toxicity of camptothecin (NSC 100880)","volume":"58","author":"Schaeppi","year":"1974","journal-title":"Cancer Chemother Rep"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0025","first-page":"515","article-title":"Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): Correlation with preclinical studies","volume":"56","author":"Muggia","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0030","first-page":"461","article-title":"Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880)","volume":"54","author":"Gottlieb","year":"1970","journal-title":"Cancer Chemother Rep"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0035","doi-asserted-by":"crossref","first-page":"14873","DOI":"10.1016\/S0021-9258(17)38654-4","article-title":"Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I","volume":"260","author":"Hsiang","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0040","first-page":"1722","article-title":"Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin","volume":"48","author":"Hsiang","year":"1988","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0045","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev.bi.54.070185.003313","article-title":"DNA topoisomerases","volume":"54","author":"Wang","year":"1985","journal-title":"Annu Rev Biochem"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0050","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1021\/bi00437a018","article-title":"On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex","volume":"28","author":"Hertzberg","year":"1989","journal-title":"Biochemistry"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0055","first-page":"5016","article-title":"Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I","volume":"49","author":"Covey","year":"1989","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0060","first-page":"5077","article-title":"Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin","volume":"49","author":"Hsiang","year":"1989","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0065","first-page":"5944","article-title":"Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors","volume":"47","author":"Kunimoto","year":"1987","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0070","first-page":"402","article-title":"Preclinical evaluation of CPT-11, a camptothecin derivative","volume":"32","author":"Bissery","year":"1991","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00262744","article-title":"Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo","volume":"21","author":"Tsuruo","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0080","first-page":"6039","article-title":"Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells","volume":"51","author":"Chen","year":"1991","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0085","first-page":"4187","article-title":"Intracellular role of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11","volume":"51","author":"Kawato","year":"1991","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0090","first-page":"115","article-title":"Phase I clinical study of CPT-11","volume":"17","author":"Taguchi","year":"1990","journal-title":"Research Group of CPT-11. Jpn J Cancer Chemother"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0095","first-page":"16","article-title":"for the CPT-11 Lung Cancer Study Group","volume":"10","author":"Fukuoka","year":"1992","journal-title":"A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0100","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1200\/JCO.1992.10.8.1225","article-title":"CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer","volume":"10","author":"Masuda","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0105","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1990.8.11.1907","article-title":"An early phase II study of CPT-11: A new derivative of camptothecin for the treatment of leukemia and lymphoma","volume":"8","author":"Ohno","year":"1990","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a059108_bb0110","first-page":"118","article-title":"Clinical studies with CPT-11: The Japanese experience","volume":"3","author":"Ogawa","year":"1992","journal-title":"Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam. Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0378-4347(92)80156-K","article-title":"Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography \u2013 application to plasma pharmacokinetic studies in cancer patients","volume":"575","author":"Barilero","year":"1992","journal-title":"J Chromatogr (Biomedical Applications)"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0125","series-title":"Pharmacokinetics","first-page":"494","author":"Gibaldi","year":"1982"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","article-title":"The current status of camptothecin analogues as antitumor agents (review)","volume":"85","author":"Slichenmyer","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0135","first-page":"121","article-title":"Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative","volume":"17","author":"Furuta","year":"1990","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0140","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/jnci\/83.16.1164","article-title":"Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer","volume":"83","author":"Negoro","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0145","first-page":"4347","article-title":"Phase I and pharmacokinetic study of the camptothecin derivative CPT-11 (irinotecan), administered on a weekly schedule in cancer patients","volume":"54","author":"de Forni","year":"1994","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0150","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1200\/JCO.1993.11.11.2194","article-title":"Phase I and pharmacokinetic trial of weekly CPT-11","volume":"11","author":"Rothenberg","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0155","first-page":"427","article-title":"Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-(4-(1-piperidino-) carbonyloxy-camptothecin (CPT-11) administered as ninety-minute infusion every 3 weeks","volume":"54","author":"Rowinsky","year":"1994","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jnci\/86.6.446","article-title":"Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea","volume":"86","author":"Abigerges","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bib0005","unstructured":"Abigerges D, Chabot GG, Armand JP et al. Phase I and pharmacokinetic studies of the camptothecin analogue irinotecan (CPT-11) administered every three weeks in cancer patients. J Clin Oncol (in press)."},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0165","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.1993.11.1.196","article-title":"CPT-11-induced cholinergic effects in cancer patients","volume":"11","author":"Gandia","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0170","first-page":"3723","article-title":"Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea","volume":"54","author":"Gupta","year":"1994","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0175","first-page":"70","article-title":"Pharmacokinetics of the topoisomerase I inhibitor, SK & F 104864","volume":"9","author":"Kuhn","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0180","first-page":"1715","article-title":"Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse","volume":"50","author":"Kaneda","year":"1990","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059108_bb0185","first-page":"1721","article-title":"Non-linear pharmacokinetics of CPT-11 in rats","volume":"50","author":"Kaneda","year":"1990","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419611245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419611245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/6\/2\/133\/494294\/6-2-133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T12:18:21Z","timestamp":1658578701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419611245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1995,2]]}},"alternative-id":["S0923753419611245"],"URL":"https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a059108","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1995,2]]}}}